Gilead Sciences (GILD) Short term Debt (2009 - 2026)

Gilead Sciences (GILD) has reported Short term Debt for 18 consecutive years, with $2.4 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Short term Debt fell 13.97% year-over-year to $2.4 billion; the trailing twelve-month figure through Jun 2026 stood at $2.4 billion (down 13.97% YoY), and the FY2025 full-year result was $2.8 billion, up 54.66% from the prior year.
• Short term Debt improved to $2.4 billion in Q2 2026 per GILD's latest filing, from $1.3 billion in the prior quarter.
• Across five years, Short term Debt topped out at $4.0 billion in Q2 2023 and bottomed at $1.0 billion in Q2 2022.
• Historically, Short term Debt has averaged $2.3 billion across 5 years, with a median of $2.3 billion in 2022.
• The sharpest annual moves came in 2023 and 2024: Short term Debt soared 295.4% in 2023, then tumbled 55.16% in 2024.
• Over 5 years, Short term Debt stood at $2.3 billion in 2022, then slipped by 20.9% to $1.8 billion in 2023, then climbed by 0.95% to $1.8 billion in 2024, then soared by 54.66% to $2.8 billion in 2025, then slipped by 14.0% to $2.4 billion in 2026.
• According to Business Quant data, Short term Debt over the past three periods registered $2.4 billion, $1.3 billion, and $2.8 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.